FreeTheAI

Parabilis Medicines Starts Zolucatetide Dose-Ranging Cohort in FAP Trial

MixedMedium impact
PBLS$26.85 −7.25%

Parabilis Medicines, Inc. (PBLS) has started a dose-ranging cohort for its drug candidate zolucatetide in patients with familial adenomatous polyposis (FAP) as part of an ongoing Phase 1/2 clinical study. The decision follows early observations showing a reduction in duodenal polyp burden in two FAP patients, along with a favorable safety profile observed so far.

The trial expansion marks progress toward establishing a registrational dose for FAP, a disease currently lacking approved systemic therapies. Despite the clinical update, shares of Parabilis Medicines fell 7.25% to $26.85 during today's trading.

Investors will be watching for further updates from the company's clinical pipeline. Additional data across FAP and desmoid tumor cohorts are expected in the first quarter of 2027, alongside plans for a Phase 3 study in desmoid tumors.

Key points

  • Parabilis Medicines began a dose-ranging FAP cohort in its Phase 1/2 study for zolucatetide.
  • Early results showed reductions in duodenal polyp burden in two patients with a favorable safety profile.
  • The company plans a Phase 3 trial in desmoid tumors and expects further clinical data in Q1 2027.
  • Shares of Parabilis Medicines (PBLS) declined 7.25% to $26.85 following the news.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is the latest update on Parabilis Medicines' zolucatetide trial?

Parabilis Medicines initiated a dose-ranging FAP cohort in its Phase 1/2 trial after observing early duodenal polyp reductions in two patients and favorable safety.

When will Parabilis Medicines release more FAP trial data?

Additional clinical data for both FAP and desmoid tumor cohorts are expected in the first quarter of 2027.

What condition is zolucatetide being tested for?

Zolucatetide is being evaluated in Phase 1/2 clinical trials for familial adenomatous polyposis (FAP) and desmoid tumors.